Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1377891

registered interest
date	12/11/2021
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Animal Experiments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, with reference to the Animals in Science Committee's report entitled Review of the harm benefit analysis in the use of animals in research, what steps her Department has taken to implement the 17 recommendations pertaining to the regulatory framework around the Animals (Scientific Procedures) Act 1986.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	73802
answer	answer is ministerial correction date of answer 23/11/2021 answer text <p>The Home Office responded to the Animals in Science Committee’s (ASC) report on a review of harm-benefit analysis in the use of animals in research on 21 May 2020.</p><p>The Home Office accepted the 17 recommendations pertaining to the Animals (Scientific Procedures) Act 1986 and indicated how it intended to implement the recommendations.</p><p>The Home Office has regularly updated the ASC and stakeholders on progress, and wider issues, at scheduled meetings. In particular, the Home Office has updated ASC and stakeholders on reforms to the regulatory delivery model, including the approach to audit, and updates to the e-licensing system. Further information is available at: <a href="http://www.gov.uk/guidance/research-and-testing-using-animals" target="_blank">www.gov.uk/guidance/research-and-testing-using-animals</a>.</p> answering member constituency East Hampshire answering member printed Damian Hinds question first answered 23/11/2021 13:33:43 answering member 3969 label Biography information for Damian Hinds previous answer version 33867 answering member constituency East Hampshire answering member printed Damian Hinds answering member 3969 label Biography information for Damian Hinds
tabling member	3960 label Biography information for Henry Smith

1378075

registered interest
date	12/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to empower clinicians to prescribe medicinal cannabis; and if he will make a statement.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	73803
answer	answer is ministerial correction date of answer 18/11/2021 answer text <p>Whether to prescribe any medicine is a clinical decision and the Government has enabled the prescription of cannabis-based products for medicinal use where it is clinically appropriate. The Chief Medical Officer and NHS England have written to doctors and pharmacists to highlight the available guidance on the prescribing and use of unlicensed medicines and to clarify the procedure for prescribing and supplying cannabis-based products for medicinal use. Health Education England has also published an e-learning module on medicinal cannabis.</p><p>The licensed cannabis-based medicine Epidyolex is prescribed and routinely funded by the National Health Service for Dravet syndrome and Lennox-Gastaut syndrome. The Medicines and Healthcare products Regulatory Agency has recently approved Epidyolex for a third form of epilepsy and it is now being assessed by the National Institute for Health and Care Excellence (NICE) for this indication. The licensed medicine Sativex is also routinely funded to treat moderate to severe spasticity in adults with multiple sclerosis. On 6 September, NHS England issued a reminder to clinical commissioning groups of NICE’s guidance relating to Sativex and will be monitoring its uptake.</p><p>The latest NICE guidelines demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based products on the NHS. The Government continues to support the establishment of clinical trials with NHS England and NHS Improvement and the National Institute for Health Research and from 1 April introduced a national patient registry to record patient outcomes. Since January 2020, the Refractory Epilepsy Specialist Clinical Advisory Service has been in place to provide advice and support for doctors to optimise the treatment of refractory epilepsy.</p><p> </p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 73766 73767 73768 73769 question first answered 18/11/2021 10:20:44 answering member 4362 label Biography information for Edward Argar
tabling member	3960 label Biography information for Henry Smith